Adam J Khorasanchi, MD
Academic Title: Assistant Professor
Research Program: Translational Therapeutics
About Me
More info forAs a medical oncologist at the OSUCCC – James, I care for patients with solid tumors. I specialize in treating people who have been hospitalized due to complications or who are experiencing serious side effects from their cancer treatments. I also serve as an assistant professor in the Division of Medical Oncology. Cancer cases are complex and require a careful and thoughtful approach. This can be a scary time for patients and I continually strive to provide the most compassionate care possible. I enjoy connecting with patients on a personal level. They can trust me to be their best advocate while they are in the hospital and to always provide effective and honest communication about their care. In addition to my clinical work, I am actively engaged in cancer research. My work has been published in multiple peer-reviewed journals. I have also been honored to present my research at major academic conferences across the country. I am a member of the American Society of Clinical Oncology and American College of Physicians. The James is an amazing institution committed to providing exemplary patient care with a multidisciplinary approach. We are leading the way in cancer research by conducting innovative trials that will significantly advance the treatments we can provide. It’s inspiring to be part of the cancer treatment team here at The James and to work with specialists who are leaders in their respective fields.
Clinical Expertise
More info for- Hospitalists
Education & Training
More info forResidency - Internal Medicine
- State University of New York at Stony Brook
101 Nicolls Rd, Stony Brook, NY
Medical School
- SUNY Downstate Health Sciences University - College of Medicine
450 Clarkson Ave, Brooklyn, NY
- State University of New York at Stony Brook
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Email:
Adam.Khorasanchi@osumc.eduPublications
More info forApril 5, 2024CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.
Khorasanchi A, Zhao S, Wei L, Li M, Ho K, Abu-Sbeih H, Goodyear E, Secor A, Shields P, He K, Kaufman J, Memmott R, Alahmadi A, Carbone D, Otterson G, Meara A, Presley C, Owen D
J Natl Compr Canc Netw
January 1, 2024Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature.
Khorasanchi A, Korman AM, Manne A, Meara A
Front Med (Lausanne)
January 1, 2023Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma.
Kwok C, Khorasanchi A, Psutka SP, Hinkley M, Dason S, Sundi D, Yang Y, Yang Y, Verschraegen C, Gross EE, Orcutt D, Yin M
Front Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Khorasanchi has reported no relationships with companies or entities.